CVRx In The News

CVRx® Announces that the First Two Patients were Treated in the Phase III Pivotal Trial Evaluating BAROSTIM THERAPY® for the Treatment of Heart Failure
June 6, 2016
CVRx® Announces Expedited Access Pathway Designation by FDA for Barostim Therapy® for the Treatment of Heart Failure in Order to Accelerate Access for US Patients
November 19, 2015
CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Session of the ESC-Heart Failure 2015 Annual Conference
May 27, 2015
CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Trial Session of the Heart Rhythm Society 2015 Annual Conference
May 26, 2015
CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Selected to be Presented in the Late-Breaking Clinical Trial Session of the Heart Rhythm Society 2015 Annual Conference
April 16, 2015
CVRx® Barostim Therapy™ for Heart Failure Clinical Trial Results Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference
March 17, 2015
CVRx® Barostim Therapy™ for Heart Failure Clinical Trial Results Selected to be Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference
February 2, 2015
CVRx® Granted Humanitarian Device Exemption Approval from FDA for Barostim neo legacy™ Hypertension Therapy Device
December 16, 2014
CVRx® Granted CE Marking of the Barostim neo System™ for Conditional MRI Compatibility
December 11, 2014
CVRx® Announces First Successful Barostim Heart Failure Commercial Implants in Europe
October 7, 2014
CVRx® Receives CE Mark Approval of the Barostim neo System™ for the Treatment of Heart Failure
September 29, 2014
CVRx® Secures $15 Million Growth Capital Facility from Silicon Valley Bank
September 22, 2014
Barostim Therapy™ Projected to be Cost-Effective in Treating Resistant Hypertension
January 7, 2014
CVRx® & DaVita Announce Strategic Partnership
November 5, 2013
CVRx® Closes $12 Million Additional Financing
October 30, 2013
CVRx®, Inc. Closes $29.6 Million Financing
July 10, 2013
Semmelweis Egyetem Kardiológiai Központ Completes First Implant of the Barostim neo™ Device for Hypertension.
May 15, 2013
CVRx® Launches European Registry to Monitor Hypertension Patients Treated with Barostim neo™ Device
July 2, 2012
CVRx® Receives CE Mark Approval and Introduces New Implantable Device for Hypertension, the Barostim neo™
August 25, 2011
Longer-Term Clinical Trial Findings Show Significant Reduction in Blood Pressure, Improvement in Heart Function with CVRx® Rheos® System
March 30, 2009
Clinical Data Presented at American Heart Association Meeting Show CVRx® Rheos® Therapy Improved Heart Structure and Function
November 11, 2008
Clinical Data Show CVRx® Rheos® Therapy Improved Heart Structure and Function in Early-Stage Heart Failure Patients
September 22, 2008
Clinical Data Show CVRx® Rheos® Therapy Improved Heart Structure and Function in Early-Stage Heart Failure Patients
September 22, 2008
CVRx®, Inc. Closes $84 Million Financing
July 29, 2008
Two-Year Clinical Trial Findings Show Significant and Persistent Reduction in Blood Pressure with CVRx® Rheos® Hypertension Therapy
June 18, 2008
CVRx®, Inc. Receives CE Mark Approval for Rheos® Baroreflex Hypertension Therapy™ System
October 31, 2007
CVRx®, Inc. Closes $65 Million Financing
May 9, 2007
CVRx, Inc. Appoints Nadim Yared President and CEO
September 18, 2006
CVRx Receives Innovator of the Year Award
August 23, 2006
CVRx Raises Additional $30 Million
May 11, 2006
CVRx Raises Additional $30 Million
May 11, 2006